Program
Cetirizine
Also written as “Cetirizine (Zyrtec)”, “AC-170 0.24%” and “Ceterizine”.
Its studies are mostly in Rhinitis, Allergic, Seasonal · Hypersensitivity · Urticaria · Conjunctivitis, Allergic · Rhinitis, Allergic, led by 12 companies.
Drug pageCetirizine: every studyMany companies study it; this page follows only the 31 they lead. All 67 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aciex Therapeuticsits history only | 70 open or running | phase 3since Apr 7, 2011 | Apr 7, 2011 | none ahead |
| GlaxoSmithKlineits history only | 50 open or running | phase 4since Aug 1, 2013 | Jun 19, 2007 | none ahead |
| JDP Therapeuticsits history only | 30 open or running | phase 3since Dec 18, 2013 | Dec 18, 2013 | none ahead |
| Johnson & Johnsonits history only | 30 open or running | phase 4since Sep 30, 2016 | Mar 23, 2011 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Feb 4, 2010 | Feb 4, 2010 | none ahead |
| Novartisits history only | 20 open or running | phase 1since Apr 13, 2009 | Apr 13, 2009 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | no phasesince Oct 17, 2008 | Oct 17, 2008 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Lunan Pharmaceutical Groupits history only | 11 open or running | phase 3since Feb 6, 2025 | Feb 6, 2025 | none ahead |
| Nicox Ophthalmicsits history only | 10 open or running | phase 3since Apr 20, 2016 | Apr 20, 2016 | none ahead |
| TerSera Therapeuticsits history only | 10 open or running | phase 2since Dec 3, 2019 | Dec 3, 2019 | none ahead |
Also a collaborator on its studies: Algorithme Pharma, ORA, Pfizer and Ohm Laboratories.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 17 studies since Jun 19, 2007.
- Mar 8, 2012Phase 3 study in Conjunctivitis, AllergicAciex Therapeutics · NCT01551056 · 91 enrolled · United States
- Sep 12, 2012Phase 3 study in Conjunctivitis, AllergicAciex Therapeutics · NCT01685242 · 100 enrolled · United States
- Jun 17, 2013Phase 3 study in Conjunctivitis, AllergicAciex Therapeutics · NCT01881113 · 101 enrolled · United States
- Aug 1, 2013Phase 4 study in RhinitisGlaxoSmithKline · NCT01916226 · 682 enrolled · United States
- Dec 18, 2013JDP Therapeutics’ first study: phase 1 study in Acute UrticariaNew to JDP TherapeuticsJDP Therapeutics · NCT02024152 · 24 enrolled · Canada
- Dec 18, 2013Phase 3 study in UrticariaJDP Therapeutics · NCT02023164 · 36 enrolled · United States, Canada
- Apr 29, 2014Phase 3 study in Atopic Disease (Including Allergic Conjunctivitis)Aciex Therapeutics · NCT02132169 · 512 enrolled · United States
- Jun 13, 2014Phase 1 study in HealthyAciex Therapeutics · NCT02173249 · 11 enrolled · United States
- Apr 20, 2016Nicox Ophthalmics’ first study: phase 3 study in Healthy SubjectsNew to Nicox OphthalmicsNicox Ophthalmics · NCT02756624 · 516 enrolled · United States
- Sep 30, 2016Phase 4 study in Rhinitis, AllergicJohnson & Johnson · NCT02932774 · 683 enrolled
- Oct 14, 2016Phase 3 study in Acute UrticariaJDP Therapeutics · NCT02935699 · 262 enrolled · United States, Canada
- Dec 10, 2018Phase 1 study in HypersensitivityJohnson & Johnson · NCT03772158 · 40 enrolled · Canada
- Dec 3, 2019TerSera Therapeutics’ first study: phase 2 study in Oncology Patients Receiving ChemotherapyNew to TerSera TherapeuticsTerSera Therapeutics · NCT04189588 · 34 enrolled · United States
- Feb 6, 2025Lunan Pharmaceutical Group’s first study: phase 3 study in Acute UrticariaNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06819774 · 284 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 31 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06819774Acute Urticaria · China | 3 | Recruiting | Lunan Pharmaceutical Group | Aug 2025 | 284 |
| NCT04189588Oncology Patients Receiving Chemotherapy · United States | 2 | Completed | TerSera Therapeutics | Nov 23, 2020 | 34 |
| NCT03772158Hypersensitivity · Canada | 1 | Completed | Johnson & Johnson | Feb 3, 2019 | 40 |
| NCT02935699Acute Urticaria · United States, Canada | 3 | Completed | JDP Therapeutics | Apr 30, 2018 | 262 |
| NCT02932774Rhinitis, Allergic | 4 | Completed | Johnson & Johnson | Jul 2001 | 683 |
| NCT02756624Healthy Subjects · United States | 3 | Completed | Nicox Ophthalmics | Aug 2016 | 516 |
| NCT02173249Healthy · United States | 1 | Completed | Aciex Therapeutics | Aug 2014 | 11 |
| NCT02132169Atopic Disease (Including Allergic Conjunctivitis) · United States | 3 | Completed | Aciex Therapeutics | Oct 2014 | 512 |
| NCT02024152Acute Urticaria · Canada | 1 | Completed | JDP Therapeutics | Jul 2011 | 24 |
| NCT02023164Urticaria · United States, Canada | 3 | Completed | JDP Therapeutics | Dec 2014 | 36 |
| NCT01916226Rhinitis · United States | 4 | Completed | GlaxoSmithKline | Oct 1, 2013 | 682 |
| NCT01881113Conjunctivitis, Allergic · United States | 3 | Completed | Aciex Therapeutics | Oct 2013 | 101 |
| NCT01685242Conjunctivitis, Allergic · United States | 3 | Completed | Aciex Therapeutics | Nov 2012 | 100 |
| NCT01551056Conjunctivitis, Allergic · United States | 3 | Completed | Aciex Therapeutics | Jun 2012 | 91 |
| NCT01495338Normal Ocular Health · United States | 1 | Completed | Aciex Therapeutics | Dec 2011 | 60 |
| NCT02447393Dermatitis · Japan | 1 | Completed | GlaxoSmithKline | Apr 30, 2008 | 20 |
| NCT01332188Conjunctivitis, Allergic · United States | 3 | Completed | Aciex Therapeutics | Jun 2011 | 101 |
| NCT01322282Hypersensitivity · Canada | 1 | Completed | Johnson & Johnson | Mar 2011 | 36 |
| NCT01064115Healthy | 1 | Completed | Dr. Reddy's Laboratories | Jan 2006 | 30 |
| NCT01064102Healthy | 1 | Completed | Dr. Reddy's Laboratories | Jan 2006 | 30 |
| NCT00972504Rhinitis, Allergic, Seasonal · Germany | 2 | Completed | GlaxoSmithKline | Aug 1, 2009 | 54 |
| NCT00881634Hypersensitivity | 1 | Completed | Novartis | Jul 2005 | 40 |
| NCT00881127Hypersensitivity | 1 | Completed | Novartis | Jul 2005 | 40 |
| NCT00864279Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2006 | 26 |
| NCT00863902Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2006 | 26 |
| NCT00851344Rhinitis, Allergic, Seasonal · Germany | 2 | Completed | GlaxoSmithKline | Nov 2008 | 54 |
| NCT00776139Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Oct 2004 | 32 |
| NCT00776022Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Apr 2005 | 32 |
| NCT00650065Healthy · United States | 1 | Completed | Viatris | Dec 2002 | 26 |
| NCT00649857Healthy · United States | 1 | Completed | Viatris | Dec 2002 | 18 |
| NCT00490204Rhinitis, Allergic, Perennial · Japan | 3 | Completed | GlaxoSmithKline | Oct 3, 2007 | 239 |
How it is read
Names in the registry
- “Cetirizine”, 6 entries
- “Cetirizine (Zyrtec)”, 5 entries
- “AC-170 0.24%”, 5 entries
- “Ceterizine”, 2 entries
- “cetirizine”, 2 entries
Codes read as this program: JDP205.
Conditions, from the studies’ own filings
- Rhinitis, Allergic, Seasonal, 8 studies
- Hypersensitivity, 6 studies
- Urticaria, 5 studies
- Conjunctivitis, Allergic, 5 studies
- Rhinitis, Allergic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.